External Beam Radiotherapy (EBRT)

RADIATION10 trials

Conditions

Bladder CancerCervical CancerEndometrial NeoplasmsGynecologic CancerLocally Advanced Cervical CancerMetastatic CancerSintilimabSolid Tumor

Phase 1

Safety and Efficacy Study of P276-00 in Combination With Radiation in Subjects With Advanced Head and Neck Cancer

CompletedNCT00899054

Piramal Enterprises LimitedSquamous Cell Carcinoma of Head and Neck

Start: 2009-08-31End: 2012-11-30Updated: 2012-11-22

External Beam Radiotherapy for Muscle Invasive Bladder Cancer

CompletedNCT02748200

University Hospital, GhentToxicity

Start: 2014-08-31End: 2020-10-31Updated: 2022-12-27

AGuIX Gadolinium-based Nanoparticles in Combination With Chemoradiation and Brachytherapy

NCT03308604

Gustave Roussy, Cancer Campus, Grand ParisGynecologic Cancer

Start: 2018-05-17End: 2024-05-31Target: 18Updated: 2021-07-07

Modern Immunotherapy in BCG-Unresponsive, BCG-Relapsing and High Risk BCG-Naive Non-Muscle Invasive Urothelial Carcinoma of the Bladder

RecruitingNCT03317158

Noah Hahn, M.D.Bladder Cancer, Urothelial Carcinoma

Start: 2017-11-21End: 2026-12-31Target: 55Updated: 2025-01-30

A Study of RP-3500 in Combination With Standard Radiation Therapy in People With Solid Tumor Cancer

Active, not recruitingNCT05566574

Memorial Sloan Kettering Cancer CenterMetastatic Cancer, Solid Tumor

Start: 2022-09-30End: 2026-09-30Updated: 2025-12-17

Phase 2

A Study of Sintilimab Combined With Concurrent Chemoradiation Therapy in Locally Advanced Cervical Cancer

NCT05105672

The Affiliated Hospital of Xuzhou Medical UniversitySintilimab, Uterine Cervical Neoplasms

Start: 2021-03-08End: 2024-03-01Target: 20Updated: 2021-12-28

Study of Chemoradiotherapy With Envafolimab For The Treatment of Locally Advanced Cervical Cancer

Not yet recruitingNCT05799469

Chongqing University Cancer HospitalLocally Advanced Cervical Cancer

Start: 2023-05-01End: 2027-12-31Target: 36Updated: 2023-04-05

Phase 3

Study of Chemoradiotherapy With or Without Pembrolizumab (MK-3475) For The Treatment of Locally Advanced Cervical Cancer (MK-3475-A18/KEYNOTE-A18/ENGOT-cx11/GOG-3047)

CompletedNCT04221945

Merck Sharp & Dohme LLCUterine Cervical Neoplasms

Start: 2020-05-12End: 2026-01-26Updated: 2026-02-20

Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)

Active, not recruitingNCT04634877

Merck Sharp & Dohme LLCEndometrial Neoplasms

Start: 2021-01-10End: 2026-09-15Target: 990Updated: 2025-06-09

A Study of Nimotuzumab Plus Concurrent Chemoradiotherapy Sequential Maintenance Treatment for Cervical Carcinoma

Not yet recruitingNCT06333821

Biotech Pharmaceutical Co., Ltd.Cervical Cancer

Start: 2024-04-01End: 2030-04-01Target: 460Updated: 2024-03-27

2025-12-11

Patient-reported outcomes from the phase 3, randomized, double-blind, placebo-controlled ENGOT-cx11/GOG-3047/KEYNOTE-A18 study of pembrolizumab plus concurrent chemoradiotherapy in participants with high-risk locally advanced cervical cancer.

2025-06-301 citations

Pembrolizumab with chemoradiotherapy in patients with high-risk locally advanced cervical cancer: Final analysis results of the phase 3, randomized, double-blind ENGOT-cx11/GOG-3047/KEYNOTE-A18 study.

Journal of Clinical Oncology2025-06-043 citations

A phase 1/2 trial of durvalumab plus intravesical gemcitabine and docetaxel in BCG-unresponsive non-muscle invasive bladder cancer patients (HCRN GU16-243: ADAPT-BLADDER Cohort 4).

Journal of Clinical Oncology2025-02-101 citations

Pembrolizumab or Placebo Plus Adjuvant Chemotherapy With or Without Radiotherapy for Newly Diagnosed, High-Risk Endometrial Cancer: Results in Mismatch Repair-Deficient Tumors

Journal of Clinical Oncology2024-10-1618 citations

Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 trial.

2024-09-1484 citations

ENGOT-en11/GOG-3053/KEYNOTE-B21: a randomised, double-blind, phase III study of pembrolizumab or placebo plus adjuvant chemotherapy with or without radiotherapy in patients with newly diagnosed, high-risk endometrial cancer.

2024-09-1445 citations

Pharmacotherapy for cervical cancer: current standard of care and new perspectives.

2024-08-271 citations

23O A randomized, phase III, double-blind study of chemoradiotherapy with or without pembrolizumab in patients with high-risk, locally advanced, cervical cancer (KEYNOTE-A18/ENGOT-cx11/GOG-3047): Results for patients enrolled in Asia

ESMO Open2024-06-012 citations

Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial.

2024-03-20228 citations

161 Pembrolizumab plus chemoradiotherapy for high-risk locally advanced cervical cancer: the randomized, double-blind, phase 3 ENGOT-Cx11/GOG-3047/KEYNOTE-A18 study

2024-03-013 citations

285 Patient-reported outcomes from the phase 3, randomized, double-blind, placebo-controlled ENGOT-Cx11/GOG 3047/KEYNOTE-A18 study of pembrolizumab plus concurrent chemoradiotherapy in patients with high-risk locally advanced cervical cancer

2024-03-011 citations

Abstract A002: Genotype-directed synthetic cytotoxicity of ATR inhibition with radiotherapy

Cancer Research2024-01-09

Phase I Trial of First-line Bintrafusp Alfa in Patients with Locally Advanced or Persistent/Recurrent/Metastatic Cervical Cancer

Clinical Cancer Research2024-01-028 citations

Phase I/II study testing the combination of AGuIX nanoparticles with radiochemotherapy and concomitant temozolomide in patients with newly diagnosed glioblastoma (NANO-GBM trial protocol)

BMC Cancer2023-04-1549 citations

Toripalimab combined with concurrent platinum-based Chemoradiotherapy in patients with locally advanced cervical Cancer: an open-label, single-arm, phase II trial.

2022-07-1910 citations

Months and Severity Score (MOSES) in a Phase III trial (PARCER): A new comprehensive method for reporting adverse events in oncology clinical trials.

2022-04-166 citations

Concurrent chemoradiation and brachytherapy alone or in combination with nelfinavir in locally advanced cervical cancer (NELCER): study protocol for a phase III trial

BMJ Open2022-04-0113 citations

EPV107/#258 ENGOT-EN11/GOG-3053/KEYNOTE-B21: phase 3 study of pembrolizumab or placebo in combination with adjuvant chemotherapy with/without radiotherapy in patients with newly diagnosed high-risk endometrial cancer

E-Posters2021-11-012 citations

EPV036/#142 European network for gynaecological oncological trial (ENGOT)-CX11/gynecologic oncology group (GOG) 3047/keynote-A18: phase 3 trial of pembrolizumab plus chemoradiotherapy in high-risk locally advanced cervical cancer

E-Posters2021-11-01

5 more papers not shown

External Beam Radiotherapy (EBRT)

Sponsors

Conditions

Phase 1

Phase 2

Phase 3

Related Papers